絞り込み

16643

広告

「elotuzumab」の検索結果

242件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

[Management of multiple myeloma in the relapsed/refractory patient].

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of NF-κB pathways.

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Treatment of relapsed multiple myeloma: Evidence-based recommendations.

Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma.

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study.

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.

Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.

Increased SLAMF7 monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].

A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.

Immunotherapy in myeloma: how far have we come?

Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.

[Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります